propafenone has been researched along with Chronic Kidney Failure in 5 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propafenone is a class Ic agent for the treatment of atrial arrhythmias with a main hepatic metabolism." | 6.68 | Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. ( Di Benedetto, A; Di Ieso, N; Liguori, A; Napoli, C; Sorice, P, 1997) |
| "Propafenone is a class Ic agent for the treatment of atrial arrhythmias with a main hepatic metabolism." | 2.68 | Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. ( Di Benedetto, A; Di Ieso, N; Liguori, A; Napoli, C; Sorice, P, 1997) |
| "In sera from patients with chronic renal failure the increase in propafenone binding ratio or the decrease in unbound fraction was associated with the increase in alpha 1-acid glycoprotein concentrations, and there was a correlation (r = 0." | 1.28 | In vitro protein binding of propafenone in normal and uraemic human sera. ( Axelson, JE; Chan, GL; Kerr, CR; McErlane, KM; Price, JD, 1989) |
| "Propafenone kinetics were studied after intravenous and oral dosing in a patient with end-stage renal disease." | 1.28 | Hemodialysis removal of propafenone. ( Burgess, ED; Duff, HJ, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Napoli, C | 1 |
| Sorice, P | 1 |
| Di Benedetto, A | 1 |
| Di Ieso, N | 1 |
| Liguori, A | 1 |
| Poirier, JM | 1 |
| Joannides, R | 1 |
| Geffroy-Josse, S | 1 |
| Fillastre, JP | 1 |
| Etienne, I | 1 |
| Burgess, E | 1 |
| Duff, H | 1 |
| Wilkes, P | 1 |
| Chan, GL | 1 |
| Axelson, JE | 1 |
| Price, JD | 1 |
| McErlane, KM | 1 |
| Kerr, CR | 1 |
| Burgess, ED | 1 |
| Duff, HJ | 1 |
1 trial available for propafenone and Chronic Kidney Failure
| Article | Year |
|---|---|
Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Urea Nitrogen; Female; Humans; Injections, Intrav | 1997 |
4 other studies available for propafenone and Chronic Kidney Failure
| Article | Year |
|---|---|
Propafenone pharmacokinetics in uremic patients treated by peritoneal dialysis.
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Kidney Failure, Chronic; Middle Aged; Peritoneal Dialysi | 1992 |
Propafenone disposition in renal insufficiency and renal failure.
Topics: Adult; Female; Half-Life; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Propafenone | 1989 |
In vitro protein binding of propafenone in normal and uraemic human sera.
Topics: Adult; Blood Proteins; Dialysis; Humans; Kidney Failure, Chronic; Male; Orosomucoid; Propafenone; Pr | 1989 |
Hemodialysis removal of propafenone.
Topics: Administration, Oral; Biological Availability; Female; Humans; Infusions, Intravenous; Kidney Failur | 1989 |